Verde Science Appoints New Chief Financial Officer with
Pharmaceutical Sector Experience
LAS VEGAS, NV -- May 7, 2015 -- (OTCPK: VRCI) Verde Science, Inc., a
Pharmaceutical Research and Development Company focused on
developing a portfolio of cannabinoid based prescription medicines
to meet patients’ needs for a wide range of medical conditions is
pleased to announce the appointment of David Alexander, CA as its
new CFO, effective immediately. David graduated with BComm in
Finance from the University of British Columbia. He has managed the
rapid growth of several early stage and startup companies. As CFO
of Arakis Energy Corporation, an international oil and gas
development company, he managed its growth from startup to over a
billion dollars in assets, and listed it on Nasdaq. Arakis was
subsequently sold to Talisman Energy Inc. He was also CFO of
Nortran Pharmaceuticals, Inc., a University of British Colombia
based pharmaceutical Research and Development Company engaged in
the development and commercialization of cardiovascular therapies.
While at Nortran, David helped secure initial and ongoing research
financing. Nortran subsequently, became into Cardiome Pharma Corp.,
a successful Vancouver BC based pharmaceutical company (Nasdaq:
CRME).
According to David, “Verde Science possesses several elements
for success in the pharmaceutical research, development and
commercialization arena. I am pleased to be part of the team that
Harp has assembled and to assist in financing and managing the
significant growth that the company envisions.”
CEO, Harp Sangha commented, “I am delighted to have David join
Verde Science at this time in our development. He is exactly what
Verde Science needs – a growth oriented CFO. His success in
managing and accelerating the growth of early stage companies,
specifically in the pharmaceutical sector should prove to be
invaluable.”
About Verde Science, Inc. (OTCPK: VRCI)
Verde Science, Inc. (trading symbol OTCPK: VRCI) is an early stage pharmaceutical
organization that has built a research team focused on developing a
portfolio of cannabinoid prescription medicines to meet patient
needs in a wide range of medical conditions. Verde's scientists
have identified a number of promising areas in which to begin its
immediate R&D program, which will initially be based in India.
The Verde Science team of inter-disciplinary researchers includes
scientists in Bioprocess Engineering, Nanotechnology, Molecular
Biology, Pharmaceutical Sciences and Bio-Medical Devices that is
focused on a streamlined approach to the development of innovative
treatment protocols aimed at capturing considerable market
share.
Contact:
www.verdescienceinc.com
Facebook: goo.gl/gxQFZz
Louis Silver, Director of Investor Relations
Tel: 1-610-710-1303
Email: lsilver@verdescienceinc.com
Safe Harbor Statements
Certain information contained in this news release constitutes
“forward-looking statements” as such term is used in applicable
United States and Canadian laws. Generally, these forward-looking
statements can be identified by the use of forward-looking
terminology such as “expects” or “does not expect”, “is expected”,
“anticipates” or “does not anticipate”, “plans”, “estimates”,
“intends” or “believes”, or that certain actions, events or results
“may”, “could”, “would”, “might” or “will be taken”, “occur”, or
“be achieved”. Forward-looking statements are based on the
opinions and estimates of management as of the date such statements
are made, and are subject to known and unknown risks, uncertainties
and other factors that may cause the actual results, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements. Many of
these factors are beyond the Company’s ability to control or
predict. Important factors that may cause actual results to differ
materially and that could impact the Company and the statements
contained in this news release can be found in the Company’s
filings with the SEC. Such risks and other factors include, among
others, the ability to locate and acquire suitable interests in
alternative medicine manufacturing operations on terms acceptable
to the Company, the availability of financing on acceptable terms,
accidents, labor disputes, acts of God and other risks of the
alternative medicine industry including, without limitation, delays
in obtaining governmental approvals or permits, title disputes or
claims limitations on insurance coverage. The Company believes that
the expectations reflected in the forward-looking statements
included in this news release are reasonable; however, no assurance
can be given that these expectations will prove to be correct, and
such forward-looking statements should not be unduly relied upon.
The Company assumes no obligation to update or supplement any
forward-looking statements whether as a result of new information,
future events or otherwise
